Procept BioRobotics announces international Hydros robot launch
March 12, 2026
Procept BioRobotics (Nasdaq:PRCT) today announced the international rollout of its next-generation Hydros robotic system for Aquablation therapy.
Procept BioRobotics (Nasdaq:PRCT) today announced the international rollout of its next-generation Hydros robotic system for Aquablation therapy.
Researchers at Boston University Chobanian & Avedisian School of Medicine now show that it is possible to remove the caudate lobe safely using a surgical robot, even in an older patient, and still remove the cancer completely.
Recent technological advances have opened new possibilities for the development of advanced medical devices, including tiny robots that can safely move inside the human body. Some of these systems could help to simplify complex medical procedures, including delicate surgeries and the targeted delivery of drugs to specific sites.
GALWAY, Ireland, Feb. 13, 2026 /PRNewswire/ — Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance of the Stealth AXiS™ surgical system, a next-generation platform that brings planning, navigation, and robotics together into a single, intelligent system for spine surgery.
Research on their new robotic crash cart (RCC)—a robotic version of the mobile drawer unit that holds supplies and equipment needed for a range of medical procedures.
Soft tissue robotic systems designed to improve surgical precision are expanding into new specialties and increasing competition for longtime industry leader Intuitive Surgical.
Intuitive Surgical (Nasdaq: ISRG)+
has received FDA clearance for “several cardiac procedures,” CEO Dave Rosa said today while announcing the surgical robotics company’s latest financial and operating results.
Retinal vein occlusion (RVO) is a severe disease that occurs when a vein in the light-sensitive layer at the back of the eye (i.e., the retina) becomes blocked, which results in a loss of vision. There are currently a few medical interventions that address RVO, including the periodic injection of medications that block the abnormal growth of blood vessels or of steroids, which reduce swelling and inflammation.
EndoQuest Robotics announced today that the FDA approved the initiation of the next and final stage of its PARADIGM trial.
IotaMotion announced today that it received FDA 510(k) clearance for expanded pediatric use of its iotaSoft insertion system.